SAN JOSE, Calif.--(BUSINESS WIRE)--Moving at the speed of AI, Spectro Cloud today unveiled its PaletteAI platform, built to transform how businesses leverage the power of Artificial Intelligence.

Shares of Abbott Laboratories (ABT) lost ~7% to reach a 52-week low on Thursday after the MedTech giant lowered its full-year earnings outlook, indicating an impact from its recent acquisition of ...

Abbott trims 2026 profit forecast on Exact deal hit, shares fall Abbott cut its annual profit forecast on Thursday due to an impact from its $23 billion acquisition of cancer test maker Exact Sciences ...

ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal brings Exact Sciences ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Elon Musk's X played a starring role in another weekend internet kerfuffle. It began when Nikita Bier, ...

It was Bloomberg that first reported rumors of the buyout on Wednesday, citing that talks were nearing fruition, according to people familiar with the matter. At the time of the article, Exact only ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...